# **Screening Libraries**

# **Product** Data Sheet

# Pentamidine isethionate

Cat. No.: HY-B0537B CAS No.: 140-64-7

Molecular Formula:  $C_{23}H_{36}N_4O_{10}S_2$ 

Molecular Weight: 592.68

Target: Parasite; Phosphatase; Fungal; Bacterial; Antibiotic

Pathway: Anti-infection; Metabolic Enzyme/Protease

4°C, sealed storage, away from moisture and light Storage:

\* In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture

and light)

# **SOLVENT & SOLUBILITY**

In Vitro

H<sub>2</sub>O: 100 mg/mL (168.73 mM; Need ultrasonic) DMSO: 100 mg/mL (168.73 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.6873 mL	8.4363 mL	16.8725 mL
	5 mM	0.3375 mL	1.6873 mL	3.3745 mL
	10 mM	0.1687 mL	0.8436 mL	1.6873 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.51 mM); Clear solution

# **BIOLOGICAL ACTIVITY**

Description

Pentamidine isethionate (MP-601205 isethionate) is an antimicrobial agent and interferes with DNA biosynthetics. Pentamidine isethionate inhibits parasite Leishmania infantum with an IC $_{50}$  of 2.5  $\mu$ M. Pentamidine isethionate is a potent and selective protein tyrosine phosphatases (PTPases) and phosphatase of regenerating liver (PRL) inhibitor. Pentamidine isethionate has the potential for Gambian trypanosomiasis, antimony-resistant leishmaniasis, and Pneumocystis carinii pneumonia treatment. Antitumor and antibacterial activities<sup>[1][2][3][4]</sup>.

IC<sub>50</sub> & Target

Trypanosoma

Leishmania

#### In Vitro

Pentamidine (0-10  $\mu$ g/mL; 6 days; WM9, DU145, C4-2, Hey, WM480, and A549 cells) treatment inhibits the growth of cancer cells in a concentration-dependent manner<sup>[1]</sup>.

The cytotoxic properties of Pentamidine isethionate towards the promastigotes of the protozoan parasite Leishmania infantum is determined. The leishmanicidal activity of Pentamidine isethionate is 60 times higher after 72 h of incubation than that of Cisplatin. Pentamidine isethionate induces a higher amount of programmed cell death (PCD) than Cisplatin, which is associated with inhibition of DNA synthesis and cell-cycle arrest in the G2/M phase. Binding of Pentamidine isethionate to calf-thymus DNA (CT-DNA) induces conformational changes in the DNA double helix, consistent with a B-->A transition. The interaction of Pentamidine isethionate with ubiquitin leads to a 6% increase in the beta-sheet content of the protein<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## Cell Viability Assay<sup>[1]</sup>

Cell Line:	WM9, DU145, C4-2, Hey, WM480, and A549 cells
Concentration:	0-10 μg/mL
Incubation Time:	6 days
Result:	The growth of all six of the cell lines in culture was inhibited in a concentration-dependent manner with complete growth inhibition of the cell lines occurring at 10 $\mu$ g/mL.

# In Vivo

Pentamidine (0.25 mg/mouse; intramuscular injection; every 2 days; for 4 weeks; athymic nude mice) treatment markedly inhibits the growth of WM9 human melanoma tumors in nude mice<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Athymic nude mice (6 weeks old) injected with WM9 ${\sf cells}^{[1]}$	
Dosage:	0.25 mg/mouse	
Administration:	Intramuscular injection; every 2 days; for 4 weeks	
Result:	Markedly inhibited the growth of WM9 human melanoma tumors in nude mice.	

## **CUSTOMER VALIDATION**

- Immunity. 2023 Feb 14;56(2):272-288.e7.
- Int J Mol Sci. 2023 Sep 5, 24(18), 13812.
- Drug Des Dev Ther. 2021 Jul 1;15:2857-2868.
- Molecules. 2020 Apr 23;25(8):1980.
- Microbiol Spectr. 2023 May 1;e0313822.

See more customer validations on www.MedChemExpress.com

## **REFERENCES**

- [1]. Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7(5):625-34.
- [2]. Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1(14):1255-64.
- $[3]. \ Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2(10): p. 1387-400.$

4]. David C. Bean, et al. Pentan	nidine: a drug to consider re-pu	rposing in the targeted treatm	ent of multi-drug resistant bacterial infection	ons? J Lab Precis Med 2017;2:49.
			dical applications. For research use or	
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExpress.cuth Junction, NJ 08852, USA	om
	Addless. I De	ser rank br, suite Q, monino	util Juliction, NJ 00032, OSA	

Page 3 of 3 www.MedChemExpress.com